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INTRODUCTION
Since its introduction, multiparametric magnetic 
resonance imaging (mpMRI) of the prostate and subsequent 
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Objective: This study’s purposes were to determine the yield of repeat direct in-bore magnetic resonance-guided prostate 
biopsy (MRGB) (MRGB-2) after the first one was found to be negative (MRGB-1), to correlate with clinical parameters, and 
to present the subgroup analyses of patients with positive repeat biopsies, despite having a negative initial biopsies.
Materials and Methods: We retrospectively included patients with MRGB-2 after a negative MRGB-1 both between January 
2006 and August 2016. This study included 62 patients (median age, 63 years; interquartile range [IQR], 58−66 years) with 
75 sampled lesions during MRGB-2 left for analysis, and 63 lesions were resampled and 12 new lesions were sampled. 
Included patients had a prostate specific antigen (PSA) at MRGB-1 of 13 ng/mL (IQR, 5.8−20.0) and a PSA at MRGB-2 of 15 
ng/mL (IQR, 9.0−22.5). All anonymized magnetic resonance imaging (MRI) data were retrospectively reassessed according 
to Prostate Imaging-Reporting and Data System version 2 by two radiologists. Images of MRGB were compared to determine 
whether the same prostate lesion was biopsied during MRGB-1 and MRGB-2. Descriptive statistics were utilized to determine 
the yield of clinically significant prostate cancer (csPCa) at MRGB-2. Gleason score of ≥ 3 + 4 was considered csPCa. 
Results: In 16/75 (21%) lesions csPCa was detected during MRGB-2. Of 63 resampled lesions, 13 (21%) harbored csPCa at 
MRGB-2. In two patients, csPCa was detected on repeat biopsy, while the volume of the lesion decreased between MRGB-1 
and MRGB-2.
Conclusion: Patients could benefit from repeat biopsy after negative initial MRGB, especially in the case of increasing PSA 
values and persisting PCa suspicion in MRI. Further research is needed to establish predictors for positive repeat targeted 
biopsies. 
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targeted biopsy improved the detection of clinically 
significant prostate cancer (csPCa), without increasing the 
detection of insignificant PCa when compared to systematic 
transrectal ultrasound (TRUS)-guided biopsy (1-3). Reported 
csPCa detection rates of targeted biopsy (e.g., fusion-
guided or direct in-bore magnetic resonance [MR] targeted) 
in men with a suspicious lesion ranged from 17–52%, 
with several reasons for this serious range. Some of these 
reasons are the diverse definitions for csPCa, the various 
thresholds from where a lesion is biopsied, the ranging 
MRI protocols and the differences in study protocols being 
either prospective or retrospective (1, 4-9). Detection rates 
for any PCa even ranges from 22−79% in men with lesions 
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MATERIALS AND METHODS
This retrospective study was approved by our Institutional 
Review Board with a waiver of informed consent (2016-2767). 
Patients
The Picture Archiving and Communication System (PACS) 
data was searched for patients who had at least two 
consecutive MRGBs in our institution between January 2006 
and August 2016. Patients were excluded if any PCa was 
detected before MRGB-1 or between MRGB-1 and MRGB-2. 
Thus, included patients did not have a biopsy proven PCa 
before MRGB-1, had a negative MRGB-1, had a lesion which 
was rebiopsied during MRGB-2 and had an mpMRI before 
MRGB-1 (Fig. 1). As a consequence of these criteria, we 
could not provide the results of the overall detection rates 
during MRGB-1 or MRGB-2. 
In 81 patients, an MRGB was performed twice in the same 
patient between January 2006 and August 2016. Of those 
patients, 19 were excluded because they had a GS 3 + 3 
after MRGB-1. 
After exclusion, 62 patients were included with 98 lesions 
biopsied during MRGB-1. Seven patients were biopsy naïve 
prior to MRGB-1. During MRGB-2, 63 of those lesions were 
rebiopsied and 12 new lesions were biopsied. In 3 out of 
these 12 new biopsied lesions, csPCa was detected. Overall, 
35 lesions biopsied during MRGB-1 were not rebiopsied during 
MRGB-2 (Fig. 1), because they were not visible anymore or 
detected on prebiopsy mpMRI (4, 6, 10, 11). Contrariwise, 
biopsy did not reveal any PCa in 21−78% of those men, 
although they had a suspicious lesion seen on mpMRI. In 
our institution, such patients, in whom direct in-bore MR-
guided biopsy (MRGB) was negative despite a suspicious 
lesion, are frequently followed by measuring the serum 
prostate specific antigen (PSA) and if required, obtaining 
another mpMRI or even repeating the MRGB. Consequently, 
additional costs are being made and patients are subjected 
to risks and the inconvenience associated with it. 
Previously, Chelluri et al. (12) described their findings 
in 90 men having a second MRI-TRUS fusion guided biopsy 
after the first one was negative, yielding 6.0% Gleason 
score (GS) ≥ 3 + 4 lesions. In addition, recently Costa et al. 
(13) presented their results yielding 40% of intermediate and 
high risk cancers with repeat targeted biopsies or surgeries 
in 38 highly suspicious lesions with an initial negative MRI-
TRUS fusion targeted prostate biopsy. 
To our knowledge, the yield of repeated MRGB in this 
particular clinical scenario is not well established. This is 
especially interesting as direct in-bore MR targeted biopsy 
is still the most accurate prostate biopsy technique (7, 
14, 15). Therefore, the aim of our paper was to determine 
the yield of repeat MRGB (MRGB-2) in patients having a 
negative first one (MRGB-1) and to correlate with clinical 
parameters and to present subgroup analyses of patients 
with positive repeat biopsies despite having negative initial 
biopsies.
Patients
Lesions
Twice MRGB
n = 81
Lesions biopsied at MRGB-1
n = 98
Lesions not rebiopsied at MRGB-2
n = 35
No csPCa
n = 9
csPCa
n = 13
New lesions biopsied at MRGB-2
n = 12
csPCa
n = 3
No csPCa
n = 50
Lesions rebiopsied at MRGB-2
n = 63
Twice MRGB and lack of any PCa at MRGB-1
n = 62
Fig. 1. Flowchart and in- and exclusion criteria of patients with repeat MRGB in our institution. cs = clinically significant, GS = 
Gleason score, MRGB = direct in-bore magnetic resonance imaging-guided biopsy, PCa = prostate cancer
Excluded (GS 3 + 3 at MRGB-1)
n = 19
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not suspicious for csPCa at mpMRI-2 (i.e., Prostate Imaging-
Reporting and Data System [PI-RADS] classification 1 or 2). 
However, because of a lack of pathologic confirmation in 
those lesions, we did not evaluate this any further. Patient 
characteristics can be found in Table 1.
mpMRI and MRGB Specifications
MRI was performed on a 3T MR-scanner (Skyra, Siemens, 
Erlangen, Germany), with a pelvic phased-array coil. 
In four patients an endorectal coil was utilized during 
first mpMRI instead of a pelvic phased-array coil. In all 
patients, tri-planar anatomical T2-weighted images (T2WI), 
axial dynamic contrast-enhanced images (DCE) and axial 
diffusion-weighted images (DWI) were usually obtained. 
However, because of the large time span in which patients 
were included, there is a slight variation in mpMRI technical 
specifications. A typical T2WI sequence had a repetition 
time (TR) of 3540 ms (range, 3000−7170), an echo time 
(TE) of 104 ms (range, 99−121), a flip angle of 120 degrees 
(range, 120−170), a turbo factor of 15 (range, 15−25), a 
matrix of 320 × 320 pixels (range, 224 x 448–384 x 384), 
and a slice thickness of 3 mm (range, 3−4), with 15−27 
slices needed to cover the entire prostate. DWI typically 
consisted of a calculated apparent diffusion coefficient 
map and multiple b-values (0, 50, 500, 800, 1400), a 
matrix of 128 x 108 pixels (range, 100 x 100−144 x 192) 
with a slice thickness of 4 mm (range, 3−5) with 20 (range, 
15−23) slices to cover the prostate. DCE was obtained 
using 15 mL gadoterate meglumine (Dotarem; Guerbet LCC, 
Bloomington, IN, USA) with an injection rate of 2.5 mL/s 
followed by a 20 mL NaCl flush, an acquisition time of 2.5 
minutes (range, 2−6) and a TR of 32 ms (range, 32−44). 
Patient characteristics are listed in Table 1, and follow up 
after MRGB-2 until September 15, 2017 were acquired from 
hospital records by one observer. 
During MRGB, patients were placed in the prone 
position with an MR-compatible needle guide rectally 
inserted. The needle guide was attached to a biopsy device 
DynaTRIM (Invivo corp., Gainesville, FL, USA). During the 
MRGB session, axial T2WI and axial DWI were obtained 
to reproduce a lesion’s location. The needle guide was 
manually positioned using true fast imaging with steady-
state free precession (TRUFI; Skyra, Siemens) images. An 
MR-compatible 18-gauge biopsy gun was used to obtain 
biopsy cores. The lengths of the obtained cores were 17 
mm. Usually, two cores per lesion are obtained. Immediately 
after the biopsy, with the biopsy needle still inserted, TRUFI 
images in two directions were obtained to confirm biopsy 
position. The position of the needle was assessed by one 
of the radiologists experienced in prostate MR readings. In 
case there is uncertainty about the accuracy of a needle, 
a third biopsy core was obtained. The ideal location of the 
Table 1. Patient and Lesion Characteristics of Included Patients
csPCa on Rebiopsy
Total
Yes (n = 13) No (n = 50)
Age (years) at MRGB1, median (IQR)    65 (58.5−67.5)  62.5 (58−66)    63 (58−66)
Prior no. TRUS biopsy, median (IQR)      2 (0.5−2.5)      2 (1−3)      2 (1−3)
Prostate volume (mL), median (IQR)    53 (47−61)    47 (41−54)    49 (43−60)
PSA density (ng/mL/mL) before MRGB-1, median (IQR) 0.18 (0.09−0.34) 0.17 (0.11−0.35) 0.17 (0.11−0.35)
PSA (ng/mL) before MRGB-1, median (IQR)   9.9 (4.8−21.2) 14.0 (6.0−19.7) 12.6 (5.8−20.0)
PSA (ng/mL) before MRGB-2, median (IQR) 12.2 (8.5−21.7) 15.6 (9.2−22.9) 15.0 (9.0−22.5)
PSA (ng/mL) increase, median (IQR)   2.7 (0.8−9.3)   1.5 (0.2−7.4)   1.8 (0.05−7.35)
MRGB-1–MRGB-2 (months), median (IQR) 11.0 (2.0−28.5) 13.0 (5.8−25.0)    13 (5.0−24.0)
Biopsies per lesion during MRGB-1, n, median (IQR)     2 (2−3)     2 (2−3)      2 (2−3)
Biopsies per lesion during MRGB-2, n, median (IQR)     2 (2−3)     2 (2−3)      2 (2−3)
PI-RADS score, % (n)
2   19 (6)   81 (26)         (32)
3   20 (1)   80 (4)         (5)
4   11 (2)   89 (17)         (19)
5   57 (4)   43 (3)         (7)
Insignificant PCa detection during MRGB-2, n       −   20     20
Analysis was done on per lesion basis. In seven patients two lesions were rebiopsied, so their age, prior No. of TRUS biopsy and PSA is 
twice included in this analysis. csPCa = clinically significant prostate cancer, IQR = interquartile range, MRGB = direct in-bore magnetic 
resonance imaging guided biopsy, PI-RADS = Prostate Imaging-Reporting and Data System, PSA = prostate-specific antigen, TRUS = 
transrectal ultrasound guided biopsy
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needle is when the tip is piercing through the lesion as the 
tip of the needle does not obtain tissue. During MRGB, no 
anesthetics were utilized. Obtained pathological tissue was 
interpreted by dedicated pathologists with 20−30 years of 
experience in prostate specimen analysis. Procedure time 
for MRGB was typically 45−60 minutes.   
mpMRI Analysis
Nowadays, in our institution, the threshold for biopsying 
a lesion is PI-RADS ≥ 3. However, as patients had mpMRI 
and MRGB before 2012, not every lesion included was 
scored according to PI-RADS. Therefore, for this study, 
mpMRI images were anonymized and they were reassessed 
according to the PI-RADS version 2 by two radiologists 
with 5 and 17 years of experience in prostate MR readings 
(respectively) (16). Disagreements were resolved by 
consulting a third reader with 12 years of experience in 
prostate MR readings. MRGB images were used to assess 
whether the same lesion was rebiopsied during MRGB-
2. Only the lesions which were biopsied twice were 
reassessed. In case other lesions were detected, we did 
not evaluate them in this study. Radiologists were blinded 
for pathological outcomes of MRGB-2 but were aware of 
the negative outcomes of MRGB-1. Lesion volume was 
calculated by the ellipsoid formula ([left-right × anterior-
posterior × cranial-caudal diameter] × π/6). The averages of 
the calculated volumes were used in the analyses. 
 
Analysis
Descriptive statistics were used for the patient, lesion 
characteristics and the detection rates of MRGB-2. Inter-
observer agreement for final PI-RADS classification between 
both radiologists was calculated using weighted kappa 
values. GS ≥ 3 + 4 was assumed to be csPCa.
RESULTS
Yield of Repeat MRGB 
During MRGB-2, 16 of 75 (21%) biopsied lesions resulted 
in csPCa. Of 63 rebiopsied lesions, 33 (52%) showed any 
Table 2. Location of Lesion Correlated to Detection of (cs) PCa
PZ TZ PZ/TZ Total
GS = 3 + 3 8 7 5 20
GS ≥ 3 + 4 7 5 1 13
No PCa 16 8 6 30
Total 31 20 12 63
GS = Gleason score, PZ = peripheral zone, TZ = transition zone, PZ/
TZ = lesions covering both PZ and TZ
A
E
B
F
C
G
D
H
Fig. 2. Example of decreasing lesion volume.
68-year-old patient with PSA of 9.9 ng/mL having mpMRI-1 and subsequent MRGB-1 of lesion which was retrospectively scored PI-RADS 2 (A-D). 
Maximal lesion diameter was 15 mm. After 11 months, his PSA increased to 12.6 ng/mL, while lesion volume decreased 0.23 mL. Maximum lesion 
diameter was unchanged. At mpMRI-2, lesion still scored PI-RADS 2 (E-H). During MRGB-2 (Fig. 3) GS 3 + 5 csPCa was detected. (A, E) axial 
T2WI, (B, F) calculated axial ADC map, (C, G) axial DWI, (D, H) color map representing dynamic contrast enhancement images. ADC = apparent 
diffusion coefficient, DWI = diffusion-weighted images, mpMRI = multiparametric magnetic resonance imaging, PI-RADS = Prostate Imaging-
Reporting and Data System, PSA = prostate specific antigen, T2WI = T2-weighted images
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PCa and 13 (21%) csPCa. Six lesions harbored GS 3 + 4, two 
GS 4 + 3, two GS 3 + 5, one GS 5 + 3 and two GS 4 + 5. The 
median volume of lesions with detected csPCa at repeat 
biopsy was 0.67 mL (0.39−2.10) and the median increase in 
volume of these lesions was 0.43 mL (interquartile range, 
-0.08−0.70). Lesion location was represented in Table 2. 
In two patients, csPCa was detected (GS 4 + 5 and 3 + 5) 
at repeat biopsy, while the volume of the lesion decreased 
between MRGB-1 and MRGB-2. In both patients, two 
radiologists agreed on the accuracy of MRGB-1 hitting the 
lesion properly. Figures 2–5 are examples of patients with 
csPCa findings at repeat biopsy. 
Characteristics of Positive Lesions on MRGB-2
At initial mpMRI, 32 lesions scored PI-RADS 2 after 
consulting the third reader. Five lesions scored PI-RADS 
3. PI-RADS 4 was scored in 19 patients. The remaining 7 
patients scored PI-RADS 5 at initial mpMRI. Detection rates 
for csPCa was 19% (6/32) in PI-RADS 2, 20% (1/5) in PI-
RADS 3, 11% (2/19) in PI-RADS 4 and 57% (4/7) in PI-
RADS 5, respectively. Any PCa was detected in 41% (13/32), 
80% (4/5), 53% (10/19), and 86% (6/7) in PI-RADS 2, 3, 4, 
and 5, respectively
A moderate interobserver agreement between both 
radiologists for the PI-RADS classification for lesions at 
mpMRI was reached with a weighted kappa value of 0.57 
(95% confidence interval, 0.36−0.78). In none of the 
patients with a decreasing PSA between MRGB-1 and MRGB-
2, csPCa was detected (Fig. 6). In patients with repeat 
biopsies, MRGB-1 was mostly performed in years 2010 and 
A B C D
Fig. 3. Confirmation scan of biopsy needle during MRGB of patient represented in Figure 2. 
A, B. Respectively axial and sagittal images of MRGB-1. C, D. Respectively axial and sagittal images of MRGB-2. Needle was assumed to properly 
sample lesion.
A
E
B
F
C
G
D
H
Fig. 4. Example of decreasing lesion volume.
52-year-old patient with PSA of 3.0 ng/mL having mpMRI-1 and subsequent MRGB-1 of lesion which was retrospectively scored PI-RADS 3 (A-D). 
Maximal lesion diameter was 9 mm. After 17 months, his PSA increased to 8.6 ng/mL and lesion volume increased 0.44 mL. Maximal lesion 
diameter increased to 13.5 mm. At mpMRI-2, lesion was scored PI-RADS 4 (E-H). During MRGB-2 (Fig. 5) GS 3 + 4 csPCa was detected. (A, E) 
axial T2WI, (B, F) calculated axial ADC map, (C, G) axial DWI, (D, H) color map representing dynamic contrast enhancement images.
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2011 (n = 34) with 7 lesions resulting in csPCa at MRGB-2. 
MRGB-1 was never performed in year 2016 (Fig. 7). 
    
Follow Up after Negative MRGB-2
Three patients with negative MRGB-2 had another MRGB 
(hereafter, MRGB-3). In none of them PCa was detected. 
Their reassessed PI-RADS scores were PI-RADS 2, 4, and 
5. In nine patients an mpMRI after MRGB-2 was obtained, 
those were assessed as being PI-RADS 2, no MRGB-3 was 
performed in those patients. In six patients no additional 
mpMRI was performed, because the PSA decreased after 
MRGB-2. In the remaining 45 patients, follow up data was 
not available.
DISCUSSION
To our knowledge, this study displayed the results of 
the first cohort of patients having repeat MRGB with 
negative first biopsies collected in more than ten years. 
We demonstrated that it might be beneficial to repeat the 
MRGB in case there is a continuing suspicion for having 
csPCa, despite a negative first MRGB, as csPCa is detected 
in 21% of 75 lesions biopsied at MRGB-2. With a csPCa 
detection rate of again 21% (n = 13/63) for resampling the 
exact same lesion, we also demonstrated that it might be 
beneficial to target a lesion which was histologically proven 
to be negative on prior MRGB.
With increasingly performed targeted biopsies, urologists 
are more often faced with patients with a suspicious lesion 
detected on mpMRI and a negative pathology outcome for 
that suspicious lesion. Yet, there is no guideline for follow 
up in such patients. Our study demonstrated that it might 
be beneficial for some patients to undergo rebiopsy such a 
lesion. This underlines the importance of follow up for some 
patients. 
Studies about a repeat biopsy or surgery after MRI-TRUS 
fusion targeted biopsy showed similar results. However, a 
head-to-head comparison is quite difficult due to the low 
number of patients in those and in our study (12, 13). 
The lengthy time range of our study allows us to raise the 
question whether our findings still apply in today’s practice. 
Therefore we reevaluated all biopsied lesions and we 
demonstrated that csPCa detection did not evidently change 
the course of the years in patients with repeat biopsy. 
In retrospect, almost half of our cohort scored PI-RADS 
2. This might be caused by an increase in experience we 
have in evaluating prostate MRI over the years. However, 
even within the cohort of patients with a reassessed PI-
RADS 2, almost 19% (n = 6/32) harbored csPCa at repeat 
biopsy. This is remarkable, as a comparable csPCa detection 
rate was seen in this study in patients with PI-RADS ≥ 3 
(23%, 7/31). Moreover, detection rates for PI-RADS 4 and 
5 described in the literature are quite higher (17-20). This 
can have several causes, for example, the relatively small 
sample size of this study making a comparison of detection 
rates with those of other studies harder. Also, the lesions 
A B C D
Fig. 5. Confirmation scan of biopsy needle during MRGB of patient represented in Figure 4. 
A, B. Respectively axial and sagittal images of MRGB-1. C, D. Respectively axial and sagittal images of MRGB-2. Needle was assumed to properly 
sample lesion.
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are already presampled making the yield of the rebiopsy 
poorer. Furthermore, involved radiologists may be biased by 
the knowledge that some of the biopsy results after MRGB-2 
were positive for csPCa and that a first biopsy in the same 
lesion was negative. However, they were not aware of which 
and how many lesions were positive for csPCa. Also, the 
range of used mpMRI sequences might cause difficulties in 
the reassessment of the obtained images. 
Intriguing are the two lesions with a decrease in 
volume and yet csPCa at repeat biopsy, as these findings 
are contrary to one’s expectation. In both lesions, the 
radiologists rated the biopsies as accurate samplings of the 
lesions during MRGB-1. This can occur, for example, in case 
of surrounding tissue reaction which could be regressive 
in control scans and thus cause a false decrease in lesion 
diameter (21). Further, we found that the time between 
MRGB-1 and MRGB-2 and PSA changes does not seems to 
influence the biopsy outcome of MRGB-2. Recommendations 
on timing of follow up in patients with change in PSA are 
therefore not possible. It appears that a rise in PSA, even 
a rapid increase in a relatively short period, seems not to 
be very helpful in selecting patients who will benefit from 
repeat biopsy. In an important amount of patients in our 
cohort with a rapid increase in PSA, csPCa was not detected 
during MRGB-2. On the other hand, none of the patients 
with a decreasing PSA had csPCa when resampling the same 
lesion. Also, timing of MRGB-1 does not seem to influence 
the results. The total number of performed MRGB-1 was 
highest in years 2010 and 2011, and also MRGB-1 of lesions 
resulting in csPCa at MRGB-2 was mostly performed within 
that time period. This might be explained by the fact that 
in our institution the total number of performed MRGBs was 
highest in that period. 
One explanation for the detection of csPCa during MRGB-
2 after a first session was negative may be the limitation 
of the biopsy technique. Although confirmation scans are 
made with the biopsy needle left in position, it remains 
difficult to assess the intralesional needle placement. 
Second, it may be explained by the biological progression. 
However, with a median time between MRGB-1 and MRGB-
2 of 11 months in patients with positive MRGB-2, it is not 
very likely. 
The most important limitation of our study was the long 
time range in which we included patients. Unfortunately, it 
was necessary to include a reasonable amount of patients. 
In a period of more than ten years, there are only 62 
patients who had a repeat MRGB after an initial negative 
MRGB in our hospital. Unfortunately, doubling our sample 
size would thus probably have taken another ten years. 
Apparently, urologists and patients are not inclined to have 
another MRGB after the first one was negative. This can be 
well explained by the additional patient burden, the costs 
and the lower probability to detect a csPCa at repeat biopsy. 
A limitation of this large time span is the introduction of 
a learning curve. Nowadays, we have a lot more experience 
in both mpMRI readings and targeted biopsiescompared 
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to ten years ago. Several studies showed the importance 
of experience in prostate MR reading and the method of 
biopsy acquisition (7, 22). To minimize this limitation, we 
reassessed all lesions according to PI-RADS version 2. Also, 
we assessed whether the biopsy needle accurately targeted 
the suspicious lesion. Due to the small sample size, we were 
not able to provide predictors for a positive repeat MRGB. 
Further, selection bias will be introduced in this study as 
we only chose resampled lesions. Included patients were 
rebiopsied, because there was some reason to believe that 
patients had csPCa regardless of the negative findings 
during initial MRGB. 
Also, a recurring limitation of all biopsy accuracy studies 
is the lack of a gold standard, for example, transperineal 
template prostate mapping or final radical prostatectomy. 
It would be extremely interesting to know whether a 
negative biopsy outcome is truly negative. Also, we only 
performed targeted biopsy without an additional systematic 
biopsy. As some studies reported csPCa detection rates up 
to 10% using systematic biopsy, which would be missed 
in a targeted only approach. Some advocate to perform 
systematic biopsy in addition to targeted biopsy (1, 22, 
23). Nonetheless, this study was only focusing on the yield 
of repeat targeted biopsy. It solely provides information on 
the utility of targeting a lesion again while it was negative 
for PCa on previous targeted biopsy. We hereby accept 
the chance that when we missed a lesion during the first 
biopsy, we might miss it again during repeat biopsy. In our 
institution, we try to minimize this chance by targeting 
each suspicious lesion at least twice. This approach, 
however, is debated as Schimmöller and colleagues 
demonstrated that there is limited benefit of targeting a 
lesion twice in the same session (24).   
Based on our results, taking the limitations into 
consideration, we can conclude that an important amount of 
patients might benefit from repeat biopsy after a negative 
MRGB. Disagreement between mpMRI lesion characteristics 
and the pathology should be evaluated carefully. Based on 
this study we cannot suggest which patients will benefit. 
Therefore, further study is warranted to establish predictors 
for a positive repeat targeted biopsy.
REFERENCES
1. Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax 
J, Shakir N, et al. Comparison of MR/ultrasound fusion-guided 
biopsy with ultrasound-guided biopsy for the diagnosis of 
prostate cancer. JAMA 2015;313:390-397
2. Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, 
Yakar D, et al. Magnetic resonance imaging guided prostate 
biopsy in men with repeat negative biopsies and increased 
prostate specific antigen. J Urol 2010;183:520-527
3. Fütterer JJ. Multiparametric MRI in the detection of clinically 
significant prostate cancer. Korean J Radiol 2017;18:597-606
4. Meng X, Rosenkrantz AB, Mendhiratta N, Fenstermaker M, 
Huang R, Wysock JS, et al. Relationship between prebiopsy 
multiparametric magnetic resonance imaging (MRI), biopsy 
indication, and MRI-ultrasound fusion-targeted prostate 
biopsy outcomes. Eur Urol 2016;69:512-517
5. Baco E, Rud E, Eri LM, Moen G, Vlatkovic L, Svindland A, 
et al. A randomized controlled trial to assess and compare 
the outcomes of two-core prostate biopsy guided by fused 
magnetic resonance and transrectal ultrasound images and 
traditional 12-core systematic biopsy. Eur Urol 2016;69:149-
156
6. Venderink W, van Luijtelaar A, Bomers JG, van der Leest 
M, Hulsbergen-van de Kaa C, Barentsz JO, et al. Results of 
targeted biopsy in men with magnetic resonance imaging 
lesions classified equivocal, likely or highly likely to be 
clinically significant prostate cancer. Eur Urol 2017 Feb 28 
[Epub]. https://doi.org/10.1016/j.eururo.2017.02.021
7. Wegelin O, van Melick HHE, Hooft L, Bosch JLHR, Reitsma 
HB, Barentsz JO, et al. Comparing three different techniques 
for magnetic resonance imaging-targeted prostate biopsies: 
a systematic review of in-bore versus magnetic resonance 
imaging-transrectal ultrasound fusion versus cognitive 
registration. Is there a preferred technique? Eur Urol 
2017;71:517-531
8. Arsov C, Rabenalt R, Blondin D, Quentin M, Hiester A, 
Godehardt E, et al. Prospective randomized trial comparing 
magnetic resonance imaging (MRI)-guided in-bore biopsy 
to MRI-ultrasound fusion and transrectal ultrasound-guided 
prostate biopsy in patients with prior negative biopsies. Eur 
Urol 2015;68:713-720
9. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan 
R, Parmar MK, et al. Diagnostic accuracy of multi-parametric 
MRI and TRUS biopsy in prostate cancer (PROMIS): a paired 
validating confirmatory study. Lancet 2017;389:815-822
10. Delongchamps NB, Peyromaure M, Schull A, Beuvon F, 
Bouazza N, Flam T, et al. Prebiopsy magnetic resonance 
imaging and prostate cancer detection: comparison of random 
and targeted biopsies. J Urol 2013;189:493-499
11. Sonn GA, Natarajan S, Margolis DJ, MacAiran M, Lieu P, Huang 
J, et al. Targeted biopsy in the detection of prostate cancer 
using an office based magnetic resonance ultrasound fusion 
device. J Urol 2013;189:86-91
12. Chelluri R, Kilchevsky A, George AK, Sidana A, Frye TP, Su 
D, et al. Prostate cancer diagnosis on repeat magnetic 
resonance imaging-transrectal ultrasound fusion biopsy of 
benign lesions: recommendations for repeat sampling. J Urol 
2016;196:62-67
13. Costa DN, Kay FU, Pedrosa I, Kolski L, Lotan Y, Roehrborn CG, 
741
Repeat MR Guided Biopsy of the Prostate
Korean J Radiol 19(4), Jul/Aug 2018kjronline.org
et al. An initial negative round of targeted biopsies in men 
with highly suspicious multiparametric magnetic resonance 
findings does not exclude clinically significant prostate 
cancer-preliminary experience. Urol Oncol 2017;35:149.
e15-e149.e21
14. Schimmöller L, Blondin D, Arsov C, Rabenalt R, Albers P, 
Antoch G, et al. MRI-guided in-bore biopsy: differences 
between prostate cancer detection and localization in 
primary and secondary biopsy settings. AJR Am J Roentgenol 
2016;206:92-99
15. Penzkofer T, Tuncali K, Fedorov A, Song SE, Tokuda J, 
Fennessy FM, et al. Transperineal in-bore 3-T MR imaging-
guided prostate biopsy: a prospective clinical observational 
study. Radiology 2015;274:170-180
16. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, 
Macura KJ, et al. PI-RADS prostate imaging - reporting and 
data system: 2015, version 2. Eur Urol 2016;69:16-40
17. Roethke MC, Kuru TH, Schultze S, Tichy D, Kopp-Schneider 
A, Fenchel M, et al. Evaluation of the ESUR PI-RADS scoring 
system for multiparametric MRI of the prostate with targeted 
MR/TRUS fusion-guided biopsy at 3.0 Tesla. Eur Radiol 
2014;24:344-352
18. Osses DF, van Asten JJ, Kieft GJ, Tijsterman JD. Prostate 
cancer detection rates of magnetic resonance imaging-guided 
prostate biopsy related to Prostate Imaging Reporting and 
Data System Score. World J Urol 2017;35:207-212
19. Felker ER, Lee-Felker SA, Feller J, Margolis DJ, Lu DS, 
Princenthal R, et al. In-bore magnetic resonance-guided 
transrectal biopsy for the detection of clinically significant 
prostate cancer. Abdom Radiol (NY) 2016;41:954-962
20. Pokorny MR, de Rooij M, Duncan E, Schröder FH, Parkinson 
R, Barentsz JO, et al. Prospective study of diagnostic 
accuracy comparing prostate cancer detection by transrectal 
ultrasound-guided biopsy versus magnetic resonance (MR) 
imaging with subsequent MR-guided biopsy in men without 
previous prostate biopsies. Eur Urol 2014;66:22-29
21. Le Nobin J, Orczyk C, Deng FM, Melamed J, Rusinek H, 
Taneja SS, et al. Prostate tumour volumes: evaluation of 
the agreement between magnetic resonance imaging and 
histology using novel co-registration software. BJU Int 
2014;114(6b):E105-E112
22. Fütterer JJ, Briganti A, De Visschere P, Emberton M, 
Giannarini G, Kirkham A, et al. Can clinically significant 
prostate cancer be detected with multiparametric magnetic 
resonance imaging? A systematic review of the literature. Eur 
Urol 2015;68:1045-1053
23. Abd-Alazeez M, Kirkham A, Ahmed HU, Arya M, Anastasiadis 
E, Charman SC, et al. Performance of multiparametric MRI in 
men at risk of prostate cancer before the first biopsy: a paired 
validating cohort study using template prostate mapping 
biopsies as the reference standard. Prostate Cancer Prostatic 
Dis 2014;17:40-46
24. Schimmöller L, Quentin M, Blondin D, Dietzel F, Hiester 
A, Schleich C, et al. Targeted MRI-guided prostate biopsy: 
are two biopsy cores per MRI-lesion required? Eur Radiol 
2016;26:3858-3864
